secwatch.observer — SEC 8-K summary
======================================

Issuer:     COOPER COMPANIES, INC. (COO)
CIK:        0000711404
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001193125-21-326207
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CooperCompanies to acquire Generate Life Sciences for $1.6B cash, expected to close Q1 2022
--------------------------------------------------------------------------------

- CooperSurgical unit will acquire Generate, a provider of donor egg/sperm, fertility cryopreservation, and newborn stem cell storage.
- Aggregate cash consideration of $1.605 billion; transaction not subject to financing condition.
- Generate reported trailing twelve-month revenue of ~$250M as of Sep 30, 2021.
- Deal expected to be accretive to non-GAAP EPS by ~$0.30 in first year after closing, excluding one-time and amortization charges.
- Closing anticipated in Cooper's first fiscal quarter of 2022 (starting Nov 1), subject to HSR and customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/711404/000119312521326207/0001193125-21-326207-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/711404/000119312521326207/d204711d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-326207

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer